First, Dr. Kim said that non-serous malignant tumors should be excluded from the study group. But practically speaking, there is no better tumor maker for malignant mucinous tumors other than CA-125, and indeed there are many other articles in the literature that have included CA-125 measurements in patients with malignant tumors other than serous types including mucinous ones.1-3 Second, we agree that platinum based chemotherapy without paclitaxel is an acceptable choice of treatment but may be not the best regimen. In our study, the number of patients who received chemotherapy without paclitaxel was 17 among 42 patients in the <75% decline group, and it was 14 among 39 of the ≥75% group, and there was no statistical difference (p=0.819).

There is substantial literature concerning CA-125 levels and ovarian cancer. Unfortunately, there have been no prospective trials assessing the relationship between survival and postoperative CA-125. Well-designed prospective trials on more specific patients would yield more worthy outcome as we already mentioned in our study.